MN1 C-terminal truncation (MCTT) syndrome is a condition characterized by intellectual disability, developmental delay, distinctive facial features, and brain abnormalities.
The prevalence of MCTT syndrome is unknown, although it is thought to be a rare disorder. At least 25 affected individuals have been described in the scientific literature.
MCTT syndrome is caused by mutations in the MN1 gene. This gene provides instructions for making a protein whose function is unclear. Based on its interaction with other proteins, the MN1 protein is thought to play a role in regulating the activity of other genes, particularly those needed for the development of the skull and brain.
All MN1 gene mutations that cause MCTT syndrome occur near the end (terminal) portion of the gene. As a result, an abnormally short (truncated) protein is produced. These mutations are reflected in the condition name, MN1 C-terminal truncation syndrome.
Research shows that a shortened MN1 protein cannot interact with other proteins, leading to a buildup of the abnormal MN1 protein in the cell nucleus. It is likely that without the normal function of the MN1 protein, the activity of certain genes involved in the development of the skull and brain is unregulated, leading to the signs and symptoms of MCTT syndrome.
MCTT syndrome is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder.
Most cases of this condition result from new (de novo) mutations in the MN1 gene that occur during the formation of reproductive cells (eggs or sperm) in an affected individual's parent or in early embryonic development. These cases occur in people with no history of the disorder in their family.
This entry is adapted from the peer-reviewed paper https://medlineplus.gov/genetics/condition/mn1-c-terminal-truncation-syndrome